Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

Direct costs of chronic obstructive pulmonary disease among managed care patients

Authors Dalal A, Christensen L, Liu F, Riedel AA

Published 30 September 2010 Volume 2010:5 Pages 341—349


Review by Single-blind

Peer reviewer comments 2

Anand A Dalal1, Laura Christensen2, Fang Liu3, Aylin A Riedel3
1US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC, USA; 2Health Economics Outcomes Research, i3 Innovus, Ann Arbor, MI, USA; 3Health Economics Outcomes Research, i3 Innovus, Eden Prairie, MN, USA

Purpose: To estimate patient- and episode-level direct costs of chronic obstructive pulmonary disease (COPD) among commercially insured patients in the US.
Methods: In this retrospective claims-based analysis, commercial enrollees with evidence of COPD were grouped into five mutually exclusive cohorts based on the most intensive level of COPD-related care they received in 2006, ie, outpatient, urgent outpatient (outpatient care in addition to a claim for an oral corticosteroid or antibiotic within seven days), emergency department (ED), standard inpatient admission, and intensive care unit (ICU) cohorts. Patient-level COPD-related annual health care costs, including patient- and payer-paid costs, were compared among the cohorts. Adjusted episode-level costs were calculated.
Results: Of the 37,089 COPD patients included in the study, 53% were in the outpatient cohort, 37% were in the urgent outpatient cohort, 3% were in the ED cohort, and the standard admission and ICU cohorts together comprised 6%. Mean (standard deviation, SD) annual COPD-related health care costs (2008 US$) increased across the cohorts (P < 0.001), ranging from $2003 ($3238) to $43,461 ($76,159) per patient. Medical costs comprised 96% of health care costs for the ICU cohort. Adjusted mean (SD) episode-level costs were $305 ($310) for an outpatient visit, $274 ($336) for an urgent outpatient visit, $327 ($65) for an ED visit, $9745 ($2968) for a standard admission, and $33,440 for an ICU stay.
Conclusion: Direct costs of COPD-related care for commercially insured patients are driven by hospital stays with or without ICU care. Exacerbation prevention resulting in reduced need for inpatient care could lower costs.

Keywords: health care cost, health expenditure, lung diseases, managed care

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States

Diette GB, Dalal AA, D’Souza AO, Lunacsek OE, Nagar SP

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:415-422

Published Date: 24 February 2015

Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims

Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:573-581

Published Date: 9 November 2011

Readers of this article also read:

Enzyme-responsive nanocomposites for wound infection prophylaxis in burn management: in vitro evaluation of their compatibility with healing processes

Grützner V, Unger RE, Baier G, Choritz L, Freese C, Böse T, Landfester K, Kirkpatrick CJ

International Journal of Nanomedicine 2015, 10:4111-4124

Published Date: 24 June 2015

Multidisciplinary treatment for peripheral arterial occlusive disease and the role of eHealth and mHealth

Fokkenrood HJP, Lauret GJ, Scheltinga MRM, Spreeuwenberg C, de Bie RA, Teijink JAW

Journal of Multidisciplinary Healthcare 2012, 5:257-263

Published Date: 8 October 2012

Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD

La Piana GE, Corda L, Bertella E, Taranto Montemurro L, Pini L, Tantucci C

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:399-405

Published Date: 12 July 2011

Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD

Chapman KR, Fogarty CM, Peckitt C, Lassen C, Jadayel D, Dederichs J, Dalvi M, Kramer B

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:353-363

Published Date: 23 June 2011

Sleep quality predicts quality of life in chronic obstructive pulmonary disease

Steven M Scharf, Nimrod Maimon, Tzahit Simon-Tuval, et al

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:1-12

Published Date: 22 December 2010

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone

Beatrix Balint, Henrik Watz, Carolynn Amos, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:311-318

Published Date: 6 September 2010